Evotec and Celgene have entered into a long-term drug discovery and development partnership to identify new therapeutics in oncology. Evotec has built one of the industry’s broadest pre-clinical discovery and development platforms. This includes a phenotypic screening platform with unique compound libraries and associated target deconvolution capabilities. The collaboration intends to leverage these capabilities with an initial focus on solid tumors. Celgene receives exclusive opt-in...